Related Experiment Video

Updated: Jul 20, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis

Raffaele Ciampi1, Yuri E Nikiforov

  • 1Department of Pathology, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA.

Endocrinology
|September 2, 2006
PubMed

Insights

Papillary thyroid cancer, the most common endocrine cancer, often involves genetic mutations in BRAF and RET genes that activate the MAPK pathway. These mutations influence tumor behavior and response to therapy, with targeted inhibitors showing promise.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Thyroid papillary carcinoma is the most prevalent endocrine malignancy.
  • Genetic alterations, particularly in BRAF and RET genes, frequently activate the MAPK signaling pathway in this cancer.
  • These genetic events are tumorigenic and impact cancer characteristics.

Purpose of the Study:

  • To investigate the role of BRAF and RET gene mutations in thyroid papillary carcinoma.
  • To understand how these mutations affect tumor aggressiveness and radioiodine therapy response.
  • To evaluate the therapeutic potential of molecular inhibitors targeting these pathways.

Main Methods:

  • Analysis of genetic alterations in BRAF and RET genes.
  • Correlation of mutations with phenotypic features and biological properties.
  • Assessment of molecular inhibitors in experimental systems.

Main Results:

  • BRAF and RET gene mutations are common drivers of thyroid papillary carcinoma.
  • Mutations correlate with tumor aggressiveness and radioiodine therapy response.
  • Molecular inhibitors targeting RET/PTC or BRAF demonstrated significant therapeutic effects in preclinical studies.

Conclusions:

  • Targeting BRAF and RET pathways offers a promising therapeutic strategy for thyroid papillary carcinoma.
  • Understanding these genetic alterations is crucial for personalized treatment approaches.
  • Clinical trials are underway to validate the efficacy of these targeted therapies.

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...